TY - JOUR
T1 - Regionally specific neuronal pathology in untreated patients with schizophrenia
T2 - A proton magnetic resonance spectroscopic imaging study
AU - Bertolino, Alessandro
AU - Callicott, Joseph H.
AU - Elman, Igor
AU - Mattay, Venkata S.
AU - Tedeschi, Gioacchino
AU - Frank, Joseph A.
AU - Breier, Alan
AU - Weinberger, Daniel R.
PY - 1998/5/1
Y1 - 1998/5/1
N2 - Background: Proton magnetic resonance spectroscopic imaging (1H-MRSI) studies have reported reductions of N-acetyl aspartate (NAA), a marker of neuronal integrity, in the hippocampal region (HIPPO) and dorsolateral prefrontal cortex (DLPFC) of pharmacologically treated patients with schizophrenia. The purpose of the present study was twofold: to exclude drug treatment as a source of the previous findings and to examine NAA relative concentrations in a unique sample of chronically untreated patients. Methods: We studied 12 medication-free patients, 5 of whom were 'drug naive' and symptomatic for a mean of 12 years, and 12 control subjects. Ratios of areas under the metabolite peaks of the proton spectra were determined [i.e., NAA/creatine (CRE), NAA/choline (CHO), CHO/CRE] for multiple cortical and subcortical regions. Hippocampal formation and frontal lobe volumes were also measured to test for correlations with 1H-MRSI data. Results: Significant reductions of NAA/CRE and NAA/CHO were found bilaterally in HlIPPO and DLPFC. There were no significant changes in CHO/CRE or in NAA ratios in any other area sampled. No significant correlation was found between metabolite ratios, length of illness, and volumes of the hippocampal region and frontal lobe. Mean ratios and effect sizes were not different in chronically ill but still medication-naive patients in comparison with subacute patients and previously studied chronic patients receiving medications. Conclusions: Bilateral reductions of NAA ratios in HIPPO and DLPFC are reliable findings. The findings implicate a relatively localized pattern of neurochemical pathology that does not appear to change with prolonged illness whether medicated or unmedicated.
AB - Background: Proton magnetic resonance spectroscopic imaging (1H-MRSI) studies have reported reductions of N-acetyl aspartate (NAA), a marker of neuronal integrity, in the hippocampal region (HIPPO) and dorsolateral prefrontal cortex (DLPFC) of pharmacologically treated patients with schizophrenia. The purpose of the present study was twofold: to exclude drug treatment as a source of the previous findings and to examine NAA relative concentrations in a unique sample of chronically untreated patients. Methods: We studied 12 medication-free patients, 5 of whom were 'drug naive' and symptomatic for a mean of 12 years, and 12 control subjects. Ratios of areas under the metabolite peaks of the proton spectra were determined [i.e., NAA/creatine (CRE), NAA/choline (CHO), CHO/CRE] for multiple cortical and subcortical regions. Hippocampal formation and frontal lobe volumes were also measured to test for correlations with 1H-MRSI data. Results: Significant reductions of NAA/CRE and NAA/CHO were found bilaterally in HlIPPO and DLPFC. There were no significant changes in CHO/CRE or in NAA ratios in any other area sampled. No significant correlation was found between metabolite ratios, length of illness, and volumes of the hippocampal region and frontal lobe. Mean ratios and effect sizes were not different in chronically ill but still medication-naive patients in comparison with subacute patients and previously studied chronic patients receiving medications. Conclusions: Bilateral reductions of NAA ratios in HIPPO and DLPFC are reliable findings. The findings implicate a relatively localized pattern of neurochemical pathology that does not appear to change with prolonged illness whether medicated or unmedicated.
KW - Drug treatment
KW - H magnetic resonance spectroscopic imaging
KW - Hipocampal area
KW - N-acetyl-aspartate
KW - Prefrontal cortex
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=0032079453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032079453&partnerID=8YFLogxK
U2 - 10.1016/S0006-3223(97)00555-6
DO - 10.1016/S0006-3223(97)00555-6
M3 - Article
C2 - 9582997
AN - SCOPUS:0032079453
SN - 0006-3223
VL - 43
SP - 641
EP - 648
JO - Biological psychiatry
JF - Biological psychiatry
IS - 9
ER -